Clinical Trial Update: Adrecizumab Dose Escalation Safety and Tolerability Evaluation (ADESTE) [Phase 2]

View source ↗

Summary

Phase 2 dose-escalation study evaluating safety and tolerability of Adrecizumab (ADESTE) in acute heart failure; status currently UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• Adrecizumab

Snippet

Sponsor: GREAT Network Italy | Conditions: Acute Heart Failure | Phase 2 | Status: UNKNOWN